| Dr Domingo A Perez, MD | |
|
#68 Ave. Santa Cruz, Suite 405 Torre San Pablo, Bayamon, PR 00961 | |
| (787) 779-0484 | |
| (787) 779-0484 |
| Full Name | Dr Domingo A Perez |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 36 Years |
| Location | #68 Ave. Santa Cruz, Bayamon, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154343978 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 9686 (Puerto Rico) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ppl Medical Csp | 9234453788 | 2 |
News Archive
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
Many people with painful, creaky knees and hips find relief after replacing their bad joints with new artificial joints made from titanium. But some of these people develop painful inflammation that can lead to bone destruction and loosening of the new joint. A new study led by researchers at the University of Medicine and Dentistry of New Jersey and published by the Journal of Immunology suggests that tiny titanium particles that flake away from the artificial joints through normal wear and tear may play a direct role in that inflammation.
Today's headlines include a new round of articles exploring recent polls and politics related to the public's view of the health law.
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Johns Hopkins bioethicists say disaster-response planning has generally overlooked the special needs of people who suffer from pre-existing and serious mental conditions. Survivors already diagnosed with schizophrenia, dementia, addictions and bipolar disorder are vulnerable long before a disaster strikes, they point out.
› Verified 2 days ago
| Entity Name | Cdt Gmsp Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417922972 PECOS PAC ID: 1355317751 Enrollment ID: O20040908000092 |
News Archive
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
Many people with painful, creaky knees and hips find relief after replacing their bad joints with new artificial joints made from titanium. But some of these people develop painful inflammation that can lead to bone destruction and loosening of the new joint. A new study led by researchers at the University of Medicine and Dentistry of New Jersey and published by the Journal of Immunology suggests that tiny titanium particles that flake away from the artificial joints through normal wear and tear may play a direct role in that inflammation.
Today's headlines include a new round of articles exploring recent polls and politics related to the public's view of the health law.
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Johns Hopkins bioethicists say disaster-response planning has generally overlooked the special needs of people who suffer from pre-existing and serious mental conditions. Survivors already diagnosed with schizophrenia, dementia, addictions and bipolar disorder are vulnerable long before a disaster strikes, they point out.
› Verified 2 days ago
| Entity Name | Ppl Medical Csp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942435094 PECOS PAC ID: 9234453788 Enrollment ID: O20150112000578 |
News Archive
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
Many people with painful, creaky knees and hips find relief after replacing their bad joints with new artificial joints made from titanium. But some of these people develop painful inflammation that can lead to bone destruction and loosening of the new joint. A new study led by researchers at the University of Medicine and Dentistry of New Jersey and published by the Journal of Immunology suggests that tiny titanium particles that flake away from the artificial joints through normal wear and tear may play a direct role in that inflammation.
Today's headlines include a new round of articles exploring recent polls and politics related to the public's view of the health law.
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Johns Hopkins bioethicists say disaster-response planning has generally overlooked the special needs of people who suffer from pre-existing and serious mental conditions. Survivors already diagnosed with schizophrenia, dementia, addictions and bipolar disorder are vulnerable long before a disaster strikes, they point out.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Domingo A Perez, MD 100 Grand Bulevard Paseos, Suite 112 Msc 333, San Juan, PR 00926-5955 Ph: (787) 779-0484 | Dr Domingo A Perez, MD #68 Ave. Santa Cruz, Suite 405 Torre San Pablo, Bayamon, PR 00961 Ph: (787) 779-0484 |
News Archive
Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.
Many people with painful, creaky knees and hips find relief after replacing their bad joints with new artificial joints made from titanium. But some of these people develop painful inflammation that can lead to bone destruction and loosening of the new joint. A new study led by researchers at the University of Medicine and Dentistry of New Jersey and published by the Journal of Immunology suggests that tiny titanium particles that flake away from the artificial joints through normal wear and tear may play a direct role in that inflammation.
Today's headlines include a new round of articles exploring recent polls and politics related to the public's view of the health law.
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Johns Hopkins bioethicists say disaster-response planning has generally overlooked the special needs of people who suffer from pre-existing and serious mental conditions. Survivors already diagnosed with schizophrenia, dementia, addictions and bipolar disorder are vulnerable long before a disaster strikes, they point out.
› Verified 2 days ago
Jannette Marie Figueroa-velez, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Paseo San Pablo, Edif Dr Arturo Cadilla Vinas Suite 104, Bayamon, PR 00960 Phone: 787-269-2442 | |
Dr. Ana I Rivera De La Vega, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Paseo San Pablo, Edif. Dr. Arturo Cadilla, Suite 201, Bayamon, PR 00961 Phone: 787-778-8774 Fax: 787-269-6190 | |
Boris M Guzman-hernandez, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: Mq10 Plaza 37, Monte Claro, Bayamon, PR 00961 Phone: 787-245-8870 Fax: 787-858-0434 | |
Jose M Rodriguez Castro, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Edif Metromedical, A- 608, Bayamon, PR 00959 Phone: 787-395-7125 Fax: 787-395-7126 | |
Dalvert H Polanco, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 100 Ave Laurel, Bayamon, PR 00956 Phone: 787-787-5151 | |
Dr. Isabel E Cestero, M. D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: Route #2 Km 11.7 Bayamon Medical Plaza, Suite 409-b, Bayamon, PR 00959 Phone: 787-786-0473 Fax: 787-786-9718 | |
Joham Senior Marino, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Piso 1 Suite 104a, Bayamon Medical Plaza, Bayamon, PR 00960 Phone: 787-798-9522 Fax: 787-798-9500 |